Figure 1 from: Goranova-Marinova V, Grekova-Kafalova D, Andreevska K, Georgieva V, Gvozdeva Y, Kassarova M, Grudeva-Popova Z, Gavazova E, Petkova V (2024) Analysis of the pharmacoeconomic effectiveness of the tyrosine kinase inhibitors therapy in patients with chronic myeloid leukemia in a Single Hematology Center in Plovdiv, Bulgaria. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e126016

Figure 1 Graphic presentation of the costs of the NHIF for original and generic medicinal products for the period 2018-2022. as a total amount and distribution by INN in BGN. Legend: TM-trademark, GN- generic name, INN- international non-proprietary name.图1 展示了2018-2022年期间国家健康保险基金（National Health Insurance Fund，NHIF）在原研药与仿制药上的开销图形化数据，以保加利亚列弗（Bulgarian Lev，BGN）为计价单位，涵盖总开销金额及按国际非专利名称（International Nonproprietary Name，INN）划分的开销分布。图例：TM-商标（Trademark，TM），GN-通用名称（Generic Name，GN），INN-国际非专利名称（International Nonproprietary Name，INN）。